Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
Kathryn LurainRamya RamaswamiRobert YarchoanThomas S UldrickPublished in: Current HIV/AIDS reports (2021)
Two recent prospective studies of anti-PD-1 agents, along with observational studies and a meta-analysis, have demonstrated acceptable safety in PLWH. Preliminary evidence indicates activity in a range of tumors and across CD4+ T cell counts. Safety and preliminary activity data suggest monoclonal antibodies targeting PD-1 or its ligand, PD-L1, are generally appropriate for PLWH and cancers for which there are FDA-approved indications. Ongoing and future trials of anti-PD-1 and anti-PD-L1 therapy alone or in combination for HIV-associated cancers may further improve outcomes for this underserved population.
Keyphrases
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- papillary thyroid
- hiv positive
- hepatitis c virus
- hiv aids
- childhood cancer
- current status
- hiv testing
- type diabetes
- big data
- stem cells
- bone marrow
- cancer therapy
- adipose tissue
- machine learning
- cell therapy
- case control
- south africa
- drug administration
- lymph node metastasis
- data analysis
- deep learning